Secondaries announced 4.1.2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Conatus Pharmaceuticals, Inc.
Symbol: CNAT
Price: Last trade $6.80
Trade Date: 4/2
Shares: 2.9 million
Underwriter(s) Stifel, Roth Capital Partners
Rating=Subscription Needed